DEA Places New ADHD Drug Centanafadine Under Schedule III Controls

Legis1

The Drug Enforcement Administration (DEA) classified the newly FDA-approved ADHD medication centanafadine (marketed as Simtriyo) under Schedule III of the Controlled Substances Act, imposing federal registration, security, and prescription requirements on its handling. This marks the first scheduling action for centanafadine, which was expedited under a 2015 law to streamline drug scheduling following FDA approval. The DEA determined that centanafadine meets Schedule III criteria, including moderate abuse potential and accepted medical use, but lower than Schedule I and II substances.

Read at Legis1

All articles from 5 November 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.

Get this news by email

Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the subscribe page.

More to read